Benito García

Benito García

Auto-generated profile, based on publicly available information

Benito García

Laboratory Medicine Department - Hospital Universitari Son Espases

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
SMSusanna E. Medellín-Garibay
Susanna E. Medellín-Garibay
BOBelén Ortiz-Martín
Belén Ortiz-Martín
ARAída Rueda-Naharro
Aída Rueda-Naharro
BGBenito García
Benito García
SRSilvia Romano-Moreno
Silvia Romano-Moreno
EBEmilia Barcia
Emilia Barcia
The objectives of this study were to characterize the population pharmacokinetics of vancomycin in trauma patients and to propose dosing schemes to optimize therapy. Trauma patients from Hospital Universitario Severo Ochoa (Spain) receiving intravenous vancomycin and routine therapeutic drug monitoring were included. Concentrations and time data were retrospectively collected, and population modelling was performed with NONMEM 7.2; internal and external validations were performed to probe the final model. Finally, several simulations were executed to propose dosing guidelines to reach expected vancomycin concentrations. A total of 118 trauma patients were included; the population was 45% males, with a mean age of 77 years (range 37–100 years) and a mean total body weight (TBW) of 72 kg (range 38–110 kg). The pharmacokinetics of vancomycin was best described by a two-compartment open model; creatinine clearance (CLCR) was related to vancomycin clearance (0.49 ± 0.04 L/h), being diminished by the presence of furosemide (0.34 ± 0.05 L/h). TBW influenced both the central volume of distribution (V1 = 0.74 ± 0.1 L/kg) and peripheral volume of distribution (V2 = 5.9 ± 2 L/kg), but patients with age >65 years showed a larger V1 (1.07 ± 0.1 L/kg). Bootstrapping was performed to internally validate the stability of the final model. External validation was developed using an alternate population of 40 patients with the same characteristics. The validated model was compared with population pharmacokinetic models previously published and showed better predictive performance for trauma patients than the current one. This final model allowed us to propose a new practical dose guideline to reach higher trough concentrations (15–20 mg/L) and AUC0–24/MIC ratios of more than 400 after 4 days of vancomycin treatment. A new population model was described for trauma patients to optimize vancomycin therapy, showing precise predictive performance to be applied for therapeutic drug monitoring and providing a new practical dose guideline that considers CLCR and concomitant administration of furosemide for these patients.

30 May 2006 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
BGBenito García
Benito García
EBEmilia Barcia
Emilia Barcia
FPFernando Pérez
Fernando Pérez
IMIrene Teresa Molina-Martínez
Irene Teresa Molina-Martínez
Objectives: To determine the pharmacokinetic parameters of gentamicin in a population of 200 premature newborns and to investigate the influence of several clinical and physiopathological covariates on the pharmacokinetics of the drug. To validate the pharmacokinetic analysis performed in another population of 50 premature newborns. Methods: A total of 200 premature newborns were evaluated at the neonatal intensive care unit of Severo Ochoa Hospital (Madrid, Spain). Four hundred and seventeen serum drug concentrations were included. Mean gestational age (GA) was 32.19 ± 2.97 weeks, mean postnatal age (PNA) was 5.49 ± 5.41 days and mean body weight (BW) was 1.68 ± 0.63 kg. Fifty additional newborns were studied for validation (mean GA 32.62 ± 3.07 weeks, mean PNA 5.17 ± 3.77 days and mean BW 1.80 ± 0.67 kg). Dosing, serum gentamicin concentrations and 15 covariates were collected. Data analysis was performed with NONMEM. One- and two-compartment open models were evaluated. Four parameters were analysed with the two-compartment open model: clearance (CL), central volume (Vc), peripheral volume (Vp) and intercompartmental clearance (Q). Results and conclusions: The two-compartment open model was found to significantly better describe gentamicin pharmacokinetics in the neonate. More than PNA or GA, creatinine clearance (CLCR) plays an important role in the elimination of gentamicin in premature newborns. Creatinine clearance is also related to GA. The appropriate dosing regimens given in accordance with the characteristics of the patients are 5 mg/kg/48 h and 4 mg/kg/24 or 36 h for neonates <32 weeks and ≥32 weeks of GA, respectively.

1 December 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
SMSusanna Edith Medellín-Garibay
Susanna Edith Medellín-Garibay
SRSilvia Romano-Moreno
Silvia Romano-Moreno
PTPilar Tejedor-Prado
Pilar Tejedor-Prado
NRNoelia Rubio-Álvaro
Noelia Rubio-Álvaro
ARAida Rueda-Naharro
Aida Rueda-Naharro
EBEmilia Barcia
Emilia Barcia
Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation (n= 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], −0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter).

21 June 2008 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
IJInmaculada JimÉNez-NÁCher
Inmaculada JimÉNez-NÁCher
BGBenito GarcÍA
Benito GarcÍA
PBPablo Barreiro
Pablo Barreiro
SRSonia Rodriguez-Novoa
Sonia Rodriguez-Novoa
JMJudit Morello
Judit Morello
VSVicente Soriano
Vicente Soriano
The choice of antiretroviral drugs has evolved over the last decade. Recognition of trends and determinants of changes may help to make predictions on prescription patterns. Longitudinal analyses were performed every 6 months from 1996 to 2006, of all HIV-infected individuals who attended at one HIV/AIDS referral centre located in Madrid, Spain. A total of 2602 different individuals attending during the study period were examined over 23 consecutive time-points. The number and proportion of patients under antiretroviral therapy significantly increased in the period 1996–99, with a plateau since then around 1100 patients, which represented around two-thirds of the patients seen at each time-point after the year 2000. The proportion of patients under antiretroviral therapy having undetectable viraemia significantly increased from 34.5% in 1996 to 80% in 2006. The relative use of nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) has risen in recent years, while prescription of non-nucleoside reverse transcriptase inhibitors has declined compared with the period 1999–2001, when it peaked. Among NRTIs, the use of zalcitabine, stavudine and didanosine has dramatically declined or vanished, while zidovudine, lamivudine, abacavir and tenofovir have gained relevance. Among PIs, indinavir and nelfinavir have almost disappeared, being replaced by ritonavir-boosted PIs, mainly atazanavir and lopinavir. After its first introduction in the year 1999, efavirenz has been generally preferred over nevirapine. The choice of antiretroviral drugs has evolved during the last decade, with safety and convenience issues driving most changes in prescription patterns, while antiviral success has dramatically increased.

1 January 1999 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
MBM. Teresa Barnés
M. Teresa Barnés
JBJosé Bascuñana
José Bascuñana
BGBenito García
Benito García
JÁJosé Luis Álvarez-Sala
José Luis Álvarez-Sala

1 June 2005 in Pharmacy World & Science
Verified
Journal Article
Closed access
PDF file
NSNerea Moyano Sierra
Nerea Moyano Sierra
BGBenito García
Benito García
JMJavier Marco
Javier Marco
SPSusana Plaza
Susana Plaza
FHFrancisco Hidalgo
Francisco Hidalgo
TBTeresa Bermejo
Teresa Bermejo